Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias;Thalidomide als behandeling bij recidiverend gastro-intestinaal bloedverlies op basis van intestinale angiodysplasieën

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 36, 2006, Pages 1994-1997

  De Koning, D B ^a   Drenth, J P H ^a   Friederich, P ^a   Nagengast, F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

AGED; ANAMNESIS; ANGIODYSPLASIA; ARTICLE; BLOOD CLOTTING; BLOOD TRANSFUSION; CASE REPORT; COLONOSCOPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMAN; IRON DEFICIENCY ANEMIA; RECURRENT DISEASE; TREATMENT FAILURE;

AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ANGIODYSPLASIA; ANGIOGENESIS INHIBITORS; BLOOD TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33749264784     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Richter JM, Hedberg SE, Athanasoulis CA, Schapiro RH. Angiodysplasia. Clinical presentation and colonoscopic diagnosis. Dig Dis Sci. 1984;29:481-5.
2. Foutch PG, Rex DK, Lieberman D. Prevalence and natural history of colonic angiodysplasia among healthy asymptomatic people. Am J Gastroenterol. 1995;90:564-7.
3. Batur P, Stewart WJ, Isaacson JH. Increased prevalence of aortic stenosis in patients with arteriovenous malformations of the gastrointestinal tract in Heyde syndrome. Arch Intern Med. 2003;163:1821-4.
4. Drenth JPH, Nagengast FM. Aortastenose en intestinaal bloedverlies uit angiodysplasieën: klepvervanging een therapeutische optie. Ned Tijdschr Geneeskd. 2000;144:2237-40.
5. Dijkhuis HJ, Hagenbeek JH, Bekker BV, Creveld S van, Monchy C de, Jonge GA de. Misvormingen na gebruik van thalidomide-preparaten in Nederland. Ned Tijdschr Geneeskd. 1962;106:1633-5.
6. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-5.
7. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003;23:2481-7.
8. Jong-van den Berg LTW de, Rutgers J, Cornel MC. Thalidomide opnieuw in de belangstelling. Ned Tijdschr Geneeskd. 1998;142:2509-12.
9. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut. 2004;53:609-12.
10. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol. 2003;98:221-2.
11. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol. 1999;94:1070-6.
12. Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118:246-50.
13. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, Zandwijk N van. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer. 2005;48:291-6.
14. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001;57:365-76.
15. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951-2.